Recent News

Through Partnership With The Chase Group, Aeglea BioTherapeutics Continues Building Rare Disease Clinical Development Leadership Team

August 12, 2019
The Chase Group is honored to continue our partnership with Aeglea BioTherapeutics as we work to build their Rare Disease Clinical Development Leadership team. As… Continue Reading →

Aeglea BioTherapeutics (NASDAQ: AGLE) Partners with The Chase Group to Build Clinical Development Team for Rapidly Expanding Genetic Rare Disease Portfolio

November 9, 2018
As a leader in engineering human enzymes to address significant unmet medical needs in rare genetic diseases and cancer, Aeglea BioTherapeutics is committed to using… Continue Reading →

Ionis Pharmaceuticals Secures Associate Director, Investor Relations

October 22, 2018
The Chase Group is pleased to announce our latest placement for Ionis Pharmaceuticals. Due to exciting organizational growth, Ionis welcomes a new Associate Director, Investor… Continue Reading →

A Successful Placement at Eisai, Inc.

August 1, 2018
The Chase Group is pleased to announce the successful completion of the Director, Clinical Research, Neuroscience at Eisai Inc. The successful candidate is a Board… Continue Reading →

Ionis Pharmaceuticals Continues to Cut to the Chase

July 30, 2018
Ionis Pharmaceuticals continues to partner with The Chase Group to find high caliber talent to join them in revolutionizing medicine through the discovery and development… Continue Reading →

Ipsen US Retains The Chase Group to Recruit a Vice President, Neurology Franchise Head

July 18, 2018
With the relocation of their headquarters to Cambridge, MA, Ipsen US is entering a new era of innovation and growth to become a leading global… Continue Reading →

The Momentum Continues at Ionis Pharmaceuticals

June 13, 2018
Ionis Pharmaceuticals has once again retained The Chase Group to assist them in finding high caliber talent to join their growing team. Due to exciting… Continue Reading →

The Chase Group Successfully Completes Vice President, Clinical Development, Respiratory for Ionis Pharmaceuticals

May 31, 2018
The Chase Group appreciates and values our continued partnership with Ionis Pharmaceuticals and is pleased to announce the successful completion of the Vice President, Clinical… Continue Reading →

Client Promotion Results in New GCP QA Talent Search

March 27, 2018
The Chase Group is proud to be working on a search for the GCP Quality Assurance and Compliance team for Ionis Pharmaceuticals. The hiring manager,… Continue Reading →

Eisai Retains The Chase Group to Find a Medical Director, Subject Matter Expert in Epilepsy

March 8, 2018
Eisai has retained The Chase Group to secure a physician for a crucial medical affairs role to serve as the Medical Lead and Subject Matter… Continue Reading →
Copyright © 1993-2024 The Chase Group. All Rights Reserved.